REGENXBIO announces completion of phase I/IIA RGX-314 clinical trial
Category: #health  By Mateen Dalal  Date: 2019-06-01
  • share
  • Twitter
  • Facebook
  • LinkedIn

REGENXBIO announces completion of phase I/IIA RGX-314 clinical trial

Every subject received one dose of RGX-314 managed by subretinal delivery.

The leading clinical-stage biotechnology company REGENXBIO Inc. has recently announced that it has finished dosing across all 5 cohorts in the Phase I/IIa medical trial of RGX-314 to cure wet age-related macular degeneration.

Steve Pakola, M.D. and Chief Medical Officer, REGENXBIO, reportedly stated that patients with wet AMD need intravitreal injections every 4-12 weeks, on average, with the existing standard of care, and the company was delighted to note long-lasting response of treatment from Cohort 3 of the RGX-314 Phase I/IIa study for wet AMD at 1 year after only one administration of RGX-314 in a hugely pre-treated patient population in an earlier provisional trial update.

Reportedly, 8 leading retinal surgery centers throughout the U.S. have participated in the Phase I/IIa RGX-314 trial. It is designed to assess the RGX-314’s safety and tolerability as a one-time treatment for patients enduring wet AMD who were treated earlier with anti-vascular endothelial growth factor (VEGF) injections. There are 42 dosed subjects across 5 escalating dose cohorts in the trial. Every subject received dose of RGX-314 managed by subretinal delivery.

Robert Avery, M.D., retina surgeon and trial investigator, California Retina Consultants, reportedly stated that the constant medical durability of effect observed one year after one-time supervision of RGX-314 in Cohort 3 represents the capability of RGX-314 to deliver substantial anti-VEGF treatment that may tolerate vision gains and alleviate treatment burden for millions of patients enduring wet AMD.

Reportedly, REGENXBIO has been planning to start a Phase IIb study in wet AMD by the end of the year 2019. Phase IIb trial will be based on the data of Phase I/IIa study which will increase clinical expansion of RGX-314 by filing an Investigational New Drug (IND) application to cure diabetic retinopathy (DR) in the second half of the year 2019.

Source credit: https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-announces-completion-dosing-phase-iiia-clinical-trial

https://www.erienewsnow.com/story/40556288/regenxbio-announces-completion-of-dosing-for-phase-iiia-clinical-trial-of-rgx-314-in-wet-amd

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

PayPal buys Happy Returns to strengthen reverse logistics system
PayPal buys Happy Returns to strengthen reverse logistics system
By Mateen Dalal

U.S. based digital payments platform, PayPal, an online payment system entity has announced the purchase of Happy Returns- a returns solution firm that provides online buyers access to simplified ways to return unwanted merchandise to retailers; elim...

YOP officially unveils YOP app to ease access to DeFi for the masses
YOP officially unveils YOP app to ease access to DeFi for the masses
By Mateen Dalal

Yield Optimization Platform and Protocol (YOP) recently declared its official launch of YOP application; the first all-in-one mobile app which makes it quite easier for everyone to access DeFi. The V0 version of the app is now available for early acc...

Singapore to create second national supercomputer with more on roadmap
Singapore to create second national supercomputer with more on roadmap
By Mateen Dalal

Following its success of the first supercomputer system, Singapore is set to build its upcoming second supercomputer system in an attempt to strengthen the local research community, offering 8X more computing capacity than its previous model. The sy...